The increased prevalence of chronic wounds of which lower extremity wounds (venous leg ulcers, diabetic foot ulcers, ischemic and other wounds) is regularly reported and with it the increase in the burden imposed by this therapeutic challenge. Every so often the mainstream press (the Internet, news dailies, and magazines) devote space to reporting another new "miracle" cure. Topical oxygen, honey, nutritional supplementations, and biologics (cell-based therapies including stem cells) are only parts of such miracle cures.
There are others too that should not be forgotten; some examples being the role of maggot debridement therapy and the use of vacuum-based technology. All these developments are usually the result of intensive, successful research and development to establish product safety and efficacy, which, when determined to be satisfactory, lead to clinical trials on wounds. Such final-phase trials are often the "bend in the river" of development leading into the wide world of the unknown. Will a product be found clinically effective? Will its use be translated into practice? What other unknowns lie ahead and how can wound healers help successfully identify and translate the use of 'miracle' cure?
In the 1980s decade, the ankle brachial pressure index was found to simply and reliably discriminate between an uncomplicated venous leg ulcer and one in which there is an element of ischemia, thereby opening possibilities of offering compression and other supportive treatments to venous leg ulcers. Some 50% of such patients derive benefits. Other physical technologies were developed and successfully tried and found useful in managing tissue at risk. Other simply marvelous developments during this period include development of new compression systems and evidence-based knowledge that graduated compression benefits venous leg ulcers, offloading is essential to relieve tissues at risk (from contact pressure on insensate, ischemic or otherwise compromised skin). Guidelines based on synthesis of evidence and sometimes clinical experience followed from relevant professional societies: presently chronic wound healing is variable, at best. Can we influence this differently?
Biologic covers are almost a marvel of tissue engineering. The best completed studies of such advances at best offer improved healing rates in small cohorts leaving unanswered how such patents are best selected, what recurrence rates follow in improved skin, and what clear economic and/or health care-related benefits are obtained? Rarely, if at all, do authors consider the role of such advanced wound product in the context of standardized care. Would a carefully constructed report from synthesized evidence help-the International Journal of Lower Extremity Wounds takes the view that such guidance is significant by its absence.
In general, products aimed to hasten and/or otherwise improve the quality of wound healing should really be tested on the bed rock of standardized care: this implies a sound diagnosis and the use of mainstay therapy. Not realistic? Difficult but certainly possible. Well-designed and carefully conducted noninferiority studies can provide a solid base for a product's advance into practice. What about the complex wounds?
Several definitions of complex wounds seem to exist. Then there are wounds that are extraordinarily difficult to manage because of multiple underlying comorbidities. Excessive exudate is one such complexity: we are now aware of some of the tissue engineering background when a wound exudate is difficult to control. Many options to manage this situation exist. In this issue of the International Journal of Lower Extremity Wounds, there is a short case report of using a modified collagen with glycerin dressing to improve the peri-wound areas in chronic wounds of different etiologies: the presence of exudate in the center of wounds was common to all. Fifty patients were carefully tested with this dressing within the context of standardized care and wound healing benefits were observed. 1 Wound healing benefits were observed; the limitations of the study were duly recognized. How did the modification affect the pH of the wound milieu? If it did, did the presence of exudate in the center of wounds beneficially interact with peri-wound pH? How did this vary with tissue moisture? The final outcomes are encouraging and thought provoking.
There is a case to test newer treatment modalities (biologics included) in large, carefully designed studies with adequate follow-up. This is resurrecting an old concept that has never been tested simply because of practical difficulties. Perhaps there is a case for professional societies to bring together workers linking hands to achieve what is everyone's aim-better healing.
